- Scribe Therapeutics to present CRISPR genome editing data at ASGCT 2025 for Duchenne Muscular Dystrophy.
- Joint presentation with Prevail Therapeutics highlights self-inactivating AAV for neurological and neuromuscular diseases.
- Event showcases Scribe's innovative X-Editor (XE) technology and collaboration with Eli Lilly's division.
Scribe Therapeutics Inc., a leading genetic medicines company, announced its participation in the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled from May 13-17, 2025, in New Orleans, LA. At this prestigious event, Scribe will present exciting advancements in CRISPR genome editing, particularly focusing on Duchenne Muscular Dystrophy (DMD), a severe neuromuscular disorder.
The company will highlight its proprietary X-Editor (XE) technology, showcasing novel genome editing strategies aimed at addressing mutations responsible for DMD. The results underscore XE's potential as a versatile platform for treating DMD and other muscle disorders, providing a glimpse into the future of genetic medicine.
In a joint presentation with Prevail Therapeutics, a division of Eli Lilly and Company (LLY, Financial), Scribe will explore the development of self-inactivating adeno-associated viral (AAV) vectors. These vectors, combined with Scribe's CRISPR-based XE technology, demonstrate potent, transient, and controllable in vivo editing capabilities in the central nervous system of mice. This collaboration has marked a significant milestone in addressing neurological and neuromuscular diseases.
The presentations will take place on May 14 and May 15, 2025, respectively, in Poster Hall I2 at the Ernest N. Morial Convention Center. Additionally, details on these findings can be accessed on the Scribe Therapeutics website.
